Exelixis Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
14.8%projected annual EPS growth
Analyst Coverage
16analysts covering
FY Revenue (est.)
$2.6Bnext fiscal year
FY EPS (est.)
$3.57next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| FDA PDUFA Target Action Date for Zanzalintinib + Atezolizumab NDA | 3 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cabozantinib Franchise Net Product Revenues (U.S.) Quarterly555MTarget: 2325000000 to 2425000000
Total Revenues Quarterly610.8MTarget: 2525000000 to 2625000000
Watch Items
- FDA PDUFA Target Action Date for Zanzalintinib in Combination with Atezolizumab for previously treated metastatic Colorectal Cancer (mCRC)Trigger: December 3, 2026Action: Monitor FDA decision and prepare for potential commercial launch execution.
- Topline Results from Phase 3 STELLAR-304 Trial in non-clear cell Renal Cell Carcinoma (nccRCC)Trigger: Second Half of 2026Action: Evaluate efficacy (PFS and ORR) to establish zanzalintinib as a frontline standard of care.
- Final Analysis of STELLAR-303 Dual Primary Endpoint (OS in Patients without Liver Metastases)Trigger: Mid-2026Action: Assess overall survival trends in the non-liver metastases subgroup to bolster commercial messaging.
Research as of 2 Sep 2026